The paper presents the proceedings of the Round Table with the participation of leading neurologists, which is devoted to chronic cerebrovascular diseases. It is noted that chronic cerebral ischemia (CCI), or dyscirculatory encephalopathy (DEP), is one of the most common neurological diagnoses in our country. The pathogenesis, clinical presentations, diagnosis and treatment of CCI (DEP) and its matching with vascular cognitive impairment (CI), which is regarded in foreign literature as the main manifestation of chronic cerebrovascular disease (CVD) were considered. The authors analyze clinical trials evaluating the efficacy of vinpocetine (Cavinton) in chronic CVD, dizziness, CI, as well as the use of new vinpocetine formulations, such as Cavinton Comforte, in various neurological diseases, dysphagia in particular, in poststroke patients.

П а т о г е н е з с к е л е т н о-м ы ш е ч н о й б о л и Боль является одним из древнейших базовых элементов системы выживания организма. Ее физиологическая функция направлена на предупреждение об опасности, повреждении целостности тканей или нарушении работы систем организма. Однако сам механизм формирования, передачи и восприятия боли часто выходит из строя, что приводит к развитию непродуктивной хронической боли (ХБ). Согласно последнему определению, ХБ-это боль, которая длится или повторяется свыше 3 мес. Проблема хронической боли настолько актуальна, что при 11-м пересмотре Международной классификации болезней она выделена в отдельную рубрику, т. е. является «родительским кодом» и далее делится на семь наиболее распространенных клинически значимых групп [1]. В структуре нозологической принадлежности неонкологической ХБ в неврологической практике преобладает скелетно-мышечная боль (78%); 2-е место занимают дисметаболические полиневропатии (алкогольные, диабетические и др.-10%); 3-е-моно-и мультиневропатии, вызванные инфекционными заболеваниями (постгерпетический ганглионеврит и др.) и травмами периферической нервной

No abstract

No abstract

The results suggest that the effectiveness of anticholinesterase treatment of Alzheimer's disease could be determined not only by the central but also peripheral cholinergic action.

No abstract

The comparative analysis of neuromorphological changes in rats of control and main groups revealed the neuroprotective and modifying effects of neuromidin on the spinal neuroplasticity.

Lumbosacral dorsopathy is the most common diagnosis in patients with lower back pain. Issues of conservative treatment of lumbosacral dorsopathies are considered based on the analysis of scientific materials contained in large databases such as PubMed, Cochrane library, MEDLINE, and eLibrary. From all publications, 40 of the most relevant works were selected and considered in detail, and key figures and short conclusions for each work are displayed in a table. Symptoms of lumbosacral dorsopathies often have an extremely negative effect on the patients ability to work and quality of life; therefore, effective and prompt treatment is important. Given the complex and multifactorial pathogenesis and multitudes of options for lumbosacral dorsopathies, conservative treatment should be complex and individualized, and drugs should have a high safety profile, especially those used in the treatment of chronic diseases. These requirements are met by some nonsteroidal anti-inflammatory drugs and co-analgesics, such as chondroprotectors and B vitamins. For the treatment of acute and exacerbated lumbosacral dorsopathies, the local use of hormonal drugs, anticonvulsants, antidepressants, muscle relaxants, etc., is possible, while treatment dosage and duration should be strictly limited. The local use of hormonal drugs and hodroprotectors such as therapeutic and diagnostic blockades is justified in the absence of contraindications and availability of opportunities, which helps reduce the likelihood of systemic adverse reactions and provides greater bioavailability.